Cellular Biomedicine Group (CBMG) Misses Q2 EPS by 7c

Cellular Biomedicine Group (NASDAQ: CBMG) reported Q2 EPS of ($0.44), $0.07 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $657 thousand versus the consensus estimate of $650 thousand.

For earnings history and earnings-related data on Cellular Biomedicine Group (CBMG) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Exclusive: BitGo says institutional conversations are shifting to tokenization
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c